PS031291 is a potent and highly selective antagonist at the chemokine receptor CCR1, which has been implicated to play a significant role in multiple inflammatory and autoimmune disease
Under the terms of the two agreements, Dyax is eligible to receive up to $500 million in license fees and milestone payments in the case of full commercial
The trial is a multi-centre, randomized, double-blind, double-dummy, crossover study to evaluate the safety and efficacy of fentanyl sublingual spray (AD 923) against an active comparator (morphine sulphate
This milestone officially marks the completion of the pivotal clinical trial of its investigational drug Sulonex (sulodexide oral gelcap) in the treatment of subjects with type 2 diabetes
Under the plan, the company will centralize the research and development activities supporting each of the company’s three main product families, as follows: Activities associated with North American
Genetic Immunity studied nine HIV infected individuals on fully suppressive antiretroviral therapy who were treated a single time with either 0.1, 0.4 or 0.8mg of multiple HIV antigens
The interim blinded HCV data showed that at the end of 48 weeks of therapy, 171 out of 553 total patients, including both treatment and control group patients,
Endologix’s Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms. Paul McCormick, president and CEO of Endologix, said: “We will begin by shipping an initial
The Phase III program is comprised of two trials involving a total of 1,500 patients with mild-to-moderate pain, including patients with osteoarthritis. Horizon Protocol HZ-CA-301 and HZ-CA-303 are
The open-label, dose escalation study is designed to define the recommended dose of XmAb2513 for subsequent trials, to determine its safety and tolerability, characterize pharmacokinetics and immunogenicity, and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.